PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

L.
1
83

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume Contents, Author index
and Subject index to
Volume 21

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors
Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology
Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics
Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
J. Gy Papp—*Szeged, Hungary*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*Cardiff, Wales*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1984, U.S. $800.00 including postage and insurance, 2 years, 1984/85, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1984 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproduction, microform or any other reproduction of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical photocopying recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0163-7258/83 $0.00 + 0.50

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 21, 1983, Numbers 1–3

CONTENTS

Number 1

PAGE

Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning: *M. F. Sugrue* 1
Implantable controlled release systems: *R. Langer* 35
Enzyme–protein conjugates: new possibilities for enzyme therapy: *M. J. Poznansky* 53
Dose-dependent pharmacokinetics: *J. M. van Rossum, G. van Lingen and J. P. T. Burgers* 77
Cellular adhension: description, methodology and drug perturbation: *S. Massa and H. B. Bosmann* 101
On the role of calcium in the mechanism of α-adrenergic agonists in rat liver: *W. M. Taylor, P. H. Reinhart and F. L. Bygrave* 125

Number 2

Molecular interactions and cellular changes during the cell cycle: *Z. Darzynkiewicz* 143
Smoking, nicotine and human performance: *K. Wesnes and D. M. Warburton* 189
Drug and hormone effects on calcium release from bone: *T. J. Martin* 209
Pharmacological approaches to influence cardiac inotropism: *H. Lüllmann, T. Peters and U. Ravens* 229
The agonistic and antagonistic properties of the high affinity antiestrogen–H1285: *T. S. Ruh and M. F. Ruh* 247
Role of ribonucleotide reductase in cell division: *J. G. Cory* 265
Regional chemotherapy of neoplastic diseases: *W. D. Ensminger and J. W. Gyves* 277

Number 3

Targeting to lympoid cells of the immune network: *W. E. Magee and S. S. Ristow* 295
Distribution of neurohypophysial hormones in the brain: *G. P. Kozlowski, G. Nilaver and E. A. Zimmerman* 325
Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions: *M. J. Kendall and L. Beeley* 351
Pokeweed antiviral protein: *J. D. Irvin* 371
Models of arthritis and the search for anti-arthritic drugs: *M. E. J. Billingham* 389
The agonistic and antagonistic effects of short acting estrogens: a review: *J. H. Clark and B. M. Markaverich* 429

AUTHOR INDEX

Beeley, L. 351
Billingham, M. E. J. 389
Bosmann, H. B. 101
Burgers, J. P. T. 77
Bygrave, F. L. 125

Clark, J. H. 429
Cory, J. G. 265

Darzynkiewicz, Z. 143

Ensminger, W. D. 277

Gyves, J. W. 277

Irvin, J. D. 371

Kendall, M. J. 351
Kozlowski, G. P. 325

Langer, R. 35
van Lingen, G. 77
Lüllmann, H. 229

Magee, W. E. 295
Markaverich, B. M. 429
Martin, T. J. 209
Massa, S. 101

Nilaver, G. 325

Peters, T. 229
Poznansky, M. J. 53

Ravens, U. 229
Reinhart, P. H. 125
Ristow, S. S. 295
van Rossum, J. M. 77
Ruh, M. F. 247
Ruh, T. S. 247

Sugrue, M. F. 1

Taylor, W. M. 125

Warburton, D. M. 189
Wesnes, K. 189

Zimmerman, E. A. 325

VOL
21
198

SUBJECT INDEX

A23107 and bone resorption 222
Action potential, inotropic agent effects 237–9
Acute phase proteins 389
  drug effects on adjuvant arthritis 398
Adenohypopophysis, projections 327, 328
Adhesion *see* cellular adhesion
α-Adrenergic agonists
  liver action and calcium 125–37
  liver mechanism of action 134
  -signal nature 134–7
  structures 126
α-Adrenergic antagonists, structures 127
β-Adrenoceptor blocking agents *see also* practolol
  adverse reactions 351–65
  carbohydrate responses 356
  carcinogenicity 360, 361
  characteristics 352
  CNS effects 356, 357
  drug interactions 358–60
  peripheral vascular response 355
  pharmacodynamic interactions 359, 360
  pharmacokinetic interactions 358, 359
  pregnancy use 362, 363
  respiratory dysfunction 354
  self poisoning 357
  sexual function 357
  short term effects 352–6
  withdrawal hazards 363–5
Adverse reaction
  β-adrenoceptor blockers 351–65
  classification 351, 352
Albumin *see* enzyme–albumin polymers
Alclofenac and adjuvant-induced arthritis 405
ALZA progestasert 41–3
AMP, cyclic
  analogs and bone resorption 221
  bone cell function 221
Anterior commissure, coronal section 334
Anti-arthritis drugs 389–422
Antibodies, targeting 297
Anticoagulation inserts 44
Antidepressants, chronic therapy and monoaminergic receptors 1–23
Antilymphocyte globulin and immunosuppression 305, 306
Antiestrogens 247 *see also* H1285
Antiviral agents *see also* pokeweed antiviral protein proteins 383, 384
Arthritis, adjuvant-induced (AA) 390–409
  adjuvant mixture 391, 392
  etiology 395–7
  assessment 397, 398
  biochemical parameters 398, 399
  drug effects 398–409
  histopathology 393–5
  phases 393
  rat strain 394
  remission-inducing drugs 401–4
  route of induction 392, 393
Arthritis, collagen-induced 409–16
  etiology 412, 413
  drug effects 413–15
  histology 411, 412
  induction and measurement 409, 410
  similarity to rheumatoid arthritis 414
  strain variation 410, 411
Arthritis, CP20961-induced 416–18
  indomethacin inhibition 416
Arthritis, model use 390–421
Arthritis, muramyl dipeptide induced 416–18
L-Asparaginase
  albumin polymer and dose–response 67
  albumin polymer and targeting 71

Benoxaprofen, adjuvant-induced arthritis 409
B lymphocytes
  antibody and immunoglobulin control 307
  idiotype marker targeting 309, 310
  markers 303, 304
Bone
  cell relationships 210
  resorption
    cellular regulation 220
    drugs affecting 221–4
    factors affecting 213–18
    inhibitors 218
    mechanisms 219–21
  structure 209, 210

Calcitonin
  bone resorption inhibition 218
  calcium homeostasis 211
  plasma calcium in rats 212
Calcium
  α-agonist pool mobilization 129–31
  bone release, factors affecting 209–24
  cell distribution, consequences of altered 131, 132
  cell flux measurements 128, 129
  heart contractile cycle 233
  heart muscle store 231–4
  hepatic α-agonist role 127, 128
  homeostasis 210–13
Ca–Mg-ATPase, cardiac plasmalemma 236, 237
  drug effects 241
Cancer
  chemotherapy *see also* regional chemotherapy
  enzyme therapy 54, 55
  implants 45
Cardiac excitation–contraction-coupling
  drug effects 237–42
  mechanisms 229
Cardiac inotropism 229–43 *see also* heart
  action potential 237–9
  calcium store 239, 240
  membrane potential 240, 241

CDP reductase activity and ATP 267
Cell cycle 143–79
  compartments and flow cytometry 173–6
  G_{1A} and G_{1B} compartments 173–5
  growth and DNA division 176, 177
  knowledge sources 143
  oncology 176–9
  quiescent compartments 175, 176
  unbalanced growth 172, 173
Cell division, ribonucleotide reductase role 265–73
Cellular adhesion 101–19
  assays 102, 103
    collection 104–7
    particle counting 107–9
  cytoskeleton modifying drugs 118, 119
  glycosidic effects 112–14
  ionic effects 117
  lectin effects 114, 115
  light scattering 110, 111
  membrane perturbants 117, 118
  surface treatments 115, 116
  trypsin effects 112
  tunicamycin effects 114
  virus effects 116, 117
  visual techniques 109, 110
Chemotherapy
  intraarterial pharmacokinetics 283–90
  regional cancer 277–90
  third space pharmacokinetics 279–83
Chlorthalidone, plasma and erythrocyte concentration curve 89
Chromatin *see also* histones
  cell cycle changes 147–52
  cellular building, steroid receptors 261, 262
  condensation mechanisms 153–5
  cycle 177, 178
    drug sensitivity 178
  non-histone proteins 157, 158
  structure and components 145–7
Chromosome, interphase condensation 158
Clearance 87
  concentration-dependent 90
Clozic, formula and adjuvant-induced arthritis 406–8
Concentration–time curves
  capacity-limited in mammalian system 93
  dose dependent kinetics 91, 92
Contraceptives, implants and inserts 41–3
Controlled-release systems 36–48
  applications 40–8
  bioreducible matrix 37
  diffusion controlled matrix 36
  diffusion controlled membrane 36
  oral 48
  osmotically controlled matrix 38
  osmotic pump 39
  pendant chain 37
  swelling controlled matrix 38

Dental uses, implants and inserts 43, 44
Diphosphonates, bone resorption 223
DNA
  denaturation *in situ* 159–61
  flow cytometry 161, 168–70
  fluorescent probes 159
  stability and quiescence 160–2
Dose-dependence 77–97
  bioavailability 94, 95
  metabolite formation 95, 96
Drug interactions 358–60

Enzymes
  administration problems 56, 57
  biopolymer carriers 58, 59
  carrier macromolecules 57–61
  lectin carriers 59, 60
  medical applications of proteolytic 55, 56
  plasma protein carriers 60, 61
Enzyme–albumin polymers 61–72
  cross-linking 63
  dose–response curve 67
  enzyme recovery 63
  hepatocyte targeting 71
  immunological properties 67–9
  insulin-mediated targeting 72
  in vivo properties 64–7
  lysosomal uptake 66
  molecular weight 62
  physical properties 62–4
  preparation 61, 62
  targeting *in vivo* 69
Enzyme-protein conjugates 53–73
Enzyme replacement therapy 53, 54
Epidermal growth factor and bone resorption 215
Estetrol structure and biosynthesis 430
Estradiol
  blood concentration 445
  chromatin–cellulose binding 261, 262
  estriol antagonism 436
  nuclear binding sites 440, 441
  nuclear translocation 257–9
  protein bound, plasma curves 88
  rat uterus weight 434, 435
  synthesis 430, 431
  toxicology 446
  uterine binding sites 254–6
    calf 256, 257
    rat 254–6
  uterine layer effects 254
  uterotrophic responses 259
    and dose 436
Estriol
  agonism, effects on uterus 437–9
  biosynthesis 430
    pregnancy 431
  blood concentration 445
  breast cancer 448, 449
  formula 429, 430
  menstrual cycle fluctuation 445
  metabolism 444
  nuclear binding sites 440, 441
  pregnancy changes 445, 446
  rat uterine weight 434, 435
  uterine growth 437
  uterotropic response and dose 436
Estrogens
  agonistic effects 437–9
  cytoplasmic receptor sites 435
  effects in males 450
  effects of short acting 429–50
  endometrial cancer 448
  menopause 447, 448
  nuclear type II binding sites 439–41
  toxicology 446
  vaginotropic response patterns 442, 443
  uterotropic events 431
Estrone, blood concentrations 445
Extrahypothalamic projections 328, 329

neurohypophyseal hormones 329
paraventricular nucleus 330, 331
source 329

Fenclofenac, adjuvant-induced arthritis 405, 506
Fetal monitoring of estrogen 449
Flow cytometry 144
cell cycle compartments 161, 168, 173
cell population kinetics 178, 179
DNA and RNA in cycling lymphocytes 170
quiescent and cycling cells 170

Glucocorticoids, bone resorption inhibition 218, 219
α-1,4-Glucosidase
-albumin bound trypsin resistance 65
lysosomal uptake 66
Gold, adjuvant-induced arthritis 401–4
effects in rats 402
formula 403

H1285-antiestrogen
agonist and antagonist properties 248, 249
analysis of action 249, 254
calf uterus binding site 256, 257
chromatin–cellular binding 261, 262
nomenclature 247
nuclear extraction 260, 261
nuclear translocation 257–9
rat uterus binding site 254–6
rat uterus histology 250–3
structure 247, 248
synthesis 247, 248
uterine layer effects 254
uterotrophic responses 259
Heart muscle
calcium fluxes 235, 236
drug effects 241, 242
calcium store 231–4
drug effects 239, 240
calcium uptake and release 236
cell membrane 230
contractile cycle and calcium 233
contractile proteins 234, 235
electrical phenomena 229–31
force–frequency and force–interval relationship 234
Na–K-ATPase 235
plasmalemma and drug interactions 240, 241
Heparin and bone resorption 221
Histones
messenger RNA synthesis 164
methylation 155
phosphorylation 150–2
poly(ADP)ribosylation 155, 156
synthesis 164, 165
ubiquitination 156
Histone H1
acetylation during cell cycle 147–9
modifications, nonmitotic cells 152, 153
phosphorylation and chromatin condensation 153–5
phosphorylation sites 150–2
structure 145, 146
Histone H1 phosphate kinases 149, 150
4-Hydroxybutyric acid, dose-dependent kinetics 92

Immune response stimulation by RNA transfer 307, 308
Immunization, inserts 44
Immunosuppression
adjuvant-induced arthritis 404
antilymphocyte globulin 305, 306
Implantable controlled release systems 35–48
Infusaid pump 278
Insulin
implanted delivery 45, 46
polymer pellets 46
Intraarterial infusion
adequacy 288, 289
cancer chemotherapy 284–90
dose–response 288
drug delivery systems 289, 290
drugs used 284
schedule dependency 288
tumor vasculature 286–8

Labetalol characteristics 352
Lactation and β-adrenoceptor blockers 363
Leukemias, antibodies reacting 310, 311
Liposomes
RNA transfer 307, 308
targeting 297
Lymphocytes, control of graft versus host disease 306, 307
Lymphoid cells *see also* B-cells, Null and T lymphocytes
maturation scheme 301
monoclonal antibody differentiation 300
surface markers 299–301
targeting 311, 312
Lymph node and target injection 312, 313
Lymphoma, antibody reacting 310, 311
Lysosomal storage disorders, enzyme deficiencies 70

Mean residence time 87
Menopause
cause 447
estrogen effects 448
symptoms 447
Metabolite formation, dose-dependent 95, 96
3α-Methyldigitoxigenin monoglucoside, action potential and contraction force 238
Micromanipulation and cellular adhesion 103–12
Microspheres, therapeutic 286–8
Microtubules, drugs affecting 222
Mithromycin and bone resorption 223, 224

Na–K-ATPase, cardiac plasmalemma 235
Neurohypophyseal hormones
anatomy 327–33
biosynthesis 325, 326
brain localization 325–43
electrophysiological studies 341
peptides coexisting 339
Neurohypophyseal peptide-containing perikarya 330
Neurohypophyseal system, magnocellular 327
Neurophysins 325
Nicotine 189
administration 202
critical flicker fusion test 203
hand tremor 203

learning 204, 205
and performance 201–5
rapid information processing 204
and smoking behavior 206, 207
Stroop effect 204
vigilance 203, 204
Non-steroidal antiinflammatory drugs
adjuvant-induced arthritis 399, 400
bone resorption 222, 223
Nuclei
acceptor sites and estrogen 261
salt extraction 260, 261
Nuclesome
cell cycle changes 147
structure 145
Null cell markers 304, 305

Ocular disease
implants and inserts 40, 41
Ocusert release curves 42
Oncology, cell cycle knowledge 176–9
Osmotic pump 39
Osteoblasts
bone resorptive process 219–21
lining 220
Osteoclasts, bone resorbing hormone action 219
Osteoclast activating factor, bone resorption 217, 218
Ovulation induction 449, 450

Parathyroid hormone
bone calcium release 213, 214
and calcium homeostasis 211
Performance
measurements 191, 192
methodology 189
nicotine effects 201–5
smoking and 189–207
Paraventricular nucleus
catechol–peptidergic interactions 333–7
neuron organization 332
D-Pencillamine 420
Peptide mapping 333–40
validation 340
Pharmacokinetics, dose-dependent 77–97
kinetic parameters 80, 81
Phenylephrine, external calcium effects in liver 130
Pokeweed antiviral protein
amino acid composition 373
antiviral potential 384, 385
cancer chemotherapy 385
cytotoxicity 381, 382
electrophoresis 375
elongation cycle inhibition 376–8
herpes simplex effects 380, 381
ionic conditions and action 378, 379
isolation 371, 372
mechanism of action 382, 383
plant virus extracts 379
properties 372–4
purification 372
ribosome inactivation 374–6
ricin similarities 379
source and discovery 371
Practolol syndrome 361
eyes 361, 362
sclerosing peritonitis 362
skin 361
Prostaglandins
bone production 217
bone resorption and potency 215–17
Protein-binding and drug dose 86
Protein synthesis, elongation cycle 377
inhibition 376–8
ricin effect 378

Rat, Brattleboro and vasopressin 343
Receptors, α-adreno
agonists 126
antagonists 127
Receptors, α_1-adreno, long term antidepressant effects 2–4
Receptors, α_2-adreno
behavioral studies 7
long term antidepressant effects 4–9
neurochemical study 5–7
Receptors, β-adreno
adverse reactions of blockers 351–65
long term antidepressants 9–14
radioligand binding 9–11
rat brain adenylate cyclase 11–13
Receptors, dopaminergic
long term antidepressant therapy 14–16
radioligand binding 14
Receptors, histaminic and long term antidepressants 19, 20
Receptors, monoaminergic and chronic antidepressant therapy 1–23
Receptors, muscarimic and long-term antidepressants 19
Receptor, estrogen
complex and estrogen treatment 437
complexes and serum albumin 444
cytoplasmic, estrogen effects 435
Receptors, opiate and long term antidepressants 20
Receptors, serotoninergic
behavioral studies 18
long term antidepressants 16–19
radioligand binding 16, 17
Receptors, uterine cytoplasmic steroid 254–63
chromatin–cellulose binding 261, 262
complex binding to reconstituted nucleoacidic protein complex 262, 263
Red blood cells, transit time 87
Regional cancer chemotherapy 277–90
infusion pump 278
intraarterial infusion 283–90
third space 279–83
Ribonucleotide reductase
bacterial, plant and mammal 266–9
mammalian cell levels and DNA synthesis 269–71
natural inhibitors 272
nucleoside triphosphate effectors 271, 272
properties and sources 273
role in cell division 265–73
substrate effectors 267
Ricin, elongation cycle inhibition 378
RNA
cell content measurement 167
cycling cells 167–70
noncycling cells 169–72
staining, flow cytometry 168–70
RNA synthesis, quiescent cell activation 165–7

Smoking
alcohol interaction 201

critical flicker fusion threshold 193
learning 199–201
methodology 190, 191
neurochemical effects 205, 206
performance 189–207
rapid information processing 197–9
simple mental efficiency 196, 197
sustained reaction-time testing 194
vigilance 193–6
Spinal cord 331
Steady state plasma drug concentration 92–4
Steady state volume of distribution 87
Steroids, adjuvant-induced arthritis 401
Styrene, dose-dependent steady-state concentrations 94
Sulphadimidine, plasma concentration curves 85
Suprachiasmatic nucleus 328
projections 329, 330
Supranucleosomal structure 146, 147

Targeting
approaches 295–9
immunoglobulin to lymphoid cancers 308, 309
lymphoid cells 311, 312
Third space
cerebrospinal fluid 279–81
direct drug infusion 282
intraperitoneal 281–3
Thyroxine, bone resorption 215
human markers 302, 303
maturation scheme 302
murine markers 301, 302
Transdermal drug delivery 47, 48
scopolamine 47
Transport, body function 77, 78
Transport function 79
linear 79, 80
nonlinearity 82–91
absorption function 82, 83
dose-dependent bioavailability 94, 95
erythrocyte binding 86–8
liver toxicity 96
metabolism 89–91
plasma protein binding 83–6
oral administration 81, 82

Uricase activity and albumin cross-linking 64

Vasopressin, structure–function relationships 341–3
Vigilance tests 193–6
Virus effects of pokeweed antiviral protein 379–81
Vitamin A and bone resorption 222
Vitamin D metabolites and analogs and bone resorption 214

Withdrawal, β-adrenoceptor blockers 363–5
mechanisms 364

L.
1
83

VOL
21
198

PHARMACOLOGY & THERAPEUTICS

Aims and Scope

Pharmacology and Therapeutics presents lucid, critical and authoritative reviews of currently important topics in pharmacology. The articles are normally specially commissioned, although uninvited review papers are occasionally published. When all the manuscripts covering a certain topic have been published, they are reappraised and, if necessary, updated, and then published as a definitive hard bound volume of the *International Encyclopedia of Pharmacology and Therapeutics*.

This policy ensures that each article is published immediately and is not delayed by the later arrival of other manuscripts for the Encyclopedia volume.

Invitation to Authors

Uninvited reviews will be welcomed for editorial consideration and authors should write to the relevant Executive Editor to obtain guidance on how to prepare their manuscripts prior to submitting their reviews.

International Encyclopedia of Pharmacology and Therapeutics—Editorial Board

W. C. Bowman—*Strathclyde*
D. C. Bovet—*Rome*
A. M. Breckenridge—*Liverpool*
A. S. V. Burgen—*London*
J. Cheymol—*Paris*
G. B. Koelle—*Philadelphia*
P. Lechat—*Paris*
H. Rašková—*Prague*
A. C. Sartorelli—*New Haven*
V. V. Zakusov—*Moscow*

Some Recent and Forthcoming Encyclopedia Volumes

Section 107 Inhibitors of Mitochondrial Function
Editors: *M. Erecinska and D. F. Wilson*
ISBN 0 08 027380 7 September 1981 348pp

Section 108 Hepatic Cytochrome P-450 Monooxygenase System
Editors: *J. B. Schenkman and D. Kupfer*
ISBN 0 08 027381 5 September 1981 864pp

Section 109 Anti-Hypertensive Drugs
Editor: *A Doyle*
ISBN 0 08 028849 9 February 1982 260pp

Section 110 The Chemotherapy of Psoriasis
Editor: *H. P. Baden*
ISBN 0 08 029823 0 July 1983 310pp

Section 111 Antiviral Chemotherapy, Vol 1
Editor: *D. Shugar*
ISBN 0 08 029821 4 June 1983 504pp

Section 112 Pain and Its Management
Editors: *N. E. Williams and H. Wilson*
ISBN 0 08 029822 2 June 1983 120pp

Section 113 Differentiation Toxicities of Insecticides and Halogenated Aromatics
Editor: *F. Matsumura*
ISBN 0 08 029826 5 November 1983 560pp

Subscribers to the Journal Pharmacology and Therapeutics may purchase individual volumes of the encyclopedia at a 20% reduction on the published price.

Send to your nearest Pergamon Office for details.